Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
NCT ID: NCT07093606
Last Updated: 2025-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2025-07-14
2026-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
NCT00359463
Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?
NCT04128358
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
NCT06137105
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
NCT02227693
Immune Thrombocytopenia Management in Adults
NCT05861297
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
this group will receive Eltrombopag tabelts
ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .
Eltrombopag
ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eltrombopag
ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Adel Alfy
Resident , Internal medicine, Faculty of Medicine Sohag university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag university hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Usama M Abdelaal, Professor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Magdy M Amin, Professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Bidika E, Fayyaz H, Salib M, Memon AN, Gowda AS, Rallabhandi B, Cancarevic I. Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment. Cureus. 2020 Aug 21;12(8):e9920. doi: 10.7759/cureus.9920.
Kuter DJ. New thrombopoietic growth factors. Blood. 2007 Jun 1;109(11):4607-16. doi: 10.1182/blood-2006-10-019315. Epub 2007 Feb 8.
Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ter Arkh. 2018 Aug 17;90(7):70-76. doi: 10.26442/terarkh201890770-76.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med--25-7-4MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.